Dr Reddy’s Laboratories said it received Brazilian approval to market and sell a generic version of Novo Nordisk’s Ozempic. ANVISA (Brazil’s health regulator) authorized generic semaglutide for adults with insufficiently controlled type 2 diabetes mellitus, alongside diet and exercise. The once-weekly treatment will be offered in 2 mg and 4 mg doses through pre-filled injector pens. Brazil has 16.6 million adults aged 20 to 79 living with diabetes and ranks sixth worldwide by the number of adults with the disease, Dr Reddy’s said. The company is relying on generic semaglutide, Ozempic’s active ingredient and also the basis of Wegovy, as a major growth driver in India and selected international markets. ANVISA rejected the application in April because it did not meet all regulatory requirements. Dr Reddy’s recalled generic semaglutide batches in Canada earlier this year after identifying an impurity in the active ingredient, but plans to relaunch the drug there this quarter and target launches in Latin America and Africa in the coming months.